Last year, the American Congress authorized a FDA breakthrough designation to speed up the approval of important drugs. Gazyva is the first step in this direction,
The producer of Gazyva is Roche’s Genentech unit based in South San Francisco. They estimated the cost of the six month treatment with Gazyva at $41,300.
The studies on Gazyva revealed at the same time the common side effects: anemia, lower levels of white blood cells, fever, muscle and bone pain.
Leukemia is an important cause of death in the U.S. According to the National Cancer Institute, about 15,000 new cases are diagnosed every year and about 4,500 die in the same interval of time. That is why Gazyva is the base of a new hope!